WASHINGTON (AP) — The Food and Drug Administration has issued a positive review of a breast cancer drug from Roche that could become the first pharmaceutical option for treating the earliest stages of the disease.
In documents posted online, FDA scientists say women who received the drug Perjeta had significantly fewer tumors than women who received older drug combinations.
The results are unusual because the drug was used prior to surgery to remove the tumors.
Based on the findings, FDA scientists recommend accelerating approval of the drug. That step is reserved for groundbreaking treatments for deadly diseases.
Perjeta was approved last summer to treat aggressive breast cancer that has spread to other parts of the body. But Roche now seeks approval to use the drug at a much earlier stage of the disease.
Copyright 2013 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
It's been 11 years since a woman was buried alive after a tractor-trailer full of sand turned over onto her car.
Roswell has seen a major increase in burglaries this year and a lack of officers might be to blame.
Celebrating one of his personal heroes, President Barack Obama praised Nelson Mandela as the last great liberator of the 20th century, urging the world to carry on his legacy by fighting inequality, poverty and discrimination.
Operation Gingerbread arrived in Albuquerque Tuesday for an event to raise funds for the Leukemia and Lymphoma Society.
The Game and Fish Department is looking for a poacher who killed four deer.
There has been a second Hantavirus death in New Mexico this year.